IPO bound? A Bay Area biotech grabs a mega-round on the road to a piv­otal neu­rode­gen­er­a­tion pro­gram

South San Fran­cis­co-based An­nex­on has added $100 mil­lion to its cash re­serves, along with a new ros­ter of mar­quee in­vestors back­ing their play on the clas­si­cal com­ple­ment path­way in­volved in neu­rode­gen­er­a­tion. And that may well fit the pro­file for an IPO — though right now every­thing seems to be work­ing on that score.

Eigh­teen months af­ter Bain and their syn­di­cate part­ners put up $75 mil­lion to fu­el clin­i­cal work, An­nex­on is back at the trough. And this time they’re adding Red­mile Group for the lead role, with sup­port­ing in­vest­ments from these new ar­rivals: Black­Rock, Deer­field Man­age­ment Com­pa­ny, Even­tide As­set Man­age­ment, Far­al­lon Cap­i­tal Man­age­ment, Janus Hen­der­son In­vestors and Lo­gos Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER